Targeting the EGFR signaling pathway in cancer therapy. - Wikidata - thesis-toulmin - TriplyDB

Targeting the EGFR signaling pathway in cancer therapy.

Targeting the EGFR signaling pathway in cancer therapy.

http://www.wikidata.org/entity/Q34246558

about

Positive and negative functions of B lymphocytes in tumors New perspectives in glioblastoma antiangiogenic therapy Targeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives Signaling cross-talk in the resistance to HER family receptor targeted therapy Inhibition of Receptor Dimerization as a Novel Negative Feedback Mechanism of EGFR Signaling Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy Cell type-specific activation of AKT and ERK signaling pathways by small negatively-charged magnetic nanoparticles XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell Protein redox chemistry: post-translational cysteine modifications that regulate signal transduction and drug pharmacology A phenotypic screening approach to identify anticancer compounds derived from marine fungi.Material basis of Chinese herbal formulas explored by combining pharmacokinetics with network pharmacology.Host matrix modulation by tumor exosomes promotes motility and invasiveness.DUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase.Infrequent ERBB2 mutations in Chinese patients with non-small cell lung cancer Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial.Thermodynamics in Gliomas: Interactions between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma The Therapeutic Benefit of Bacterial Membrane Vesicles.Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung Cancer ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2.Integrative analysis reveals disease-associated genes and biomarkers for prostate cancer progression.A molecular prognostic model predicts esophageal squamous cell carcinoma prognosis.EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.Neddylation dysfunction in Alzheimer's disease.Plakophilin-2 promotes tumor development by enhancing ligand-dependent and -independent epidermal growth factor receptor dimerization and activation.FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway.Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.Profiling and metaanalysis of epidermal keratinocytes responses to epidermal growth factor.Dynamic multiprotein assemblies shape the spatial structure of cell signaling Development of an epidermal growth factor derivative with EGFR blocking activity Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.RTK/ERK pathway under natural selection associated with prostate cancer.HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.Functional aspects of the EGF-induced MAP kinase cascade: a complex self-organizing system approach Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway Hypermethylated Epidermal growth factor receptor (EGFR) promoter is associated with gastric cancer

P2860

Q26743398-7AC70EFA-72C4-4249-9B6C-5C9BEBD96720 Q26746028-BD2D6A00-A0B8-4A51-BAC7-169B1C39D530 Q26798203-6A93D3D2-351A-49F5-B788-D2B41DF5C12D Q26852578-6ACFF0FB-6BAA-4716-8706-362465F21EDB Q27027778-0EC17CE2-5E63-428A-94DC-70893DD0357D Q27314725-0D8C5184-EDA3-4E0B-85F8-AF51C2D0D915 Q27701980-ED5B03A7-D803-4EF2-A7C6-51547D755DB5 Q28078129-9747EC0D-F2F3-4AA6-B124-DEB7BE431CDE Q28391111-A862377C-E984-4912-9F04-3FFDD65E45DC Q30354484-D9A1A3AA-6C87-4A51-8A25-00A6D4400B23 Q30368044-E780210C-AF2A-4999-A812-DC9C48A253F2 Q30415131-F475D2D2-6FBB-45B2-A4BB-AEAA1A4B099B Q30457612-7B527767-EBCB-461D-BC8E-AA82EDB9BDE1 Q30541999-CE20E884-BDD8-48C7-8C0B-A51C91EBEF6E Q30579145-2EDBE86D-1AE0-41E8-9B27-AEBF427D40C0 Q33586108-C1335F45-3BB6-4F18-959E-4F1855B7A37E Q33654186-07398497-03C1-4F8A-A0AB-87901554740C Q33733218-50EB266B-52F6-4FA6-A44E-72123209B048 Q33748280-DF977DCC-FC89-4C53-998B-E9A9176D1949 Q33839021-69A6E67D-1DE6-44FC-A8BF-B8F9F4C85865 Q33859503-2D68712F-7B3F-44AE-88F8-9D2E7B9F1B4F Q33861296-B9EB5721-58B9-4FEE-8947-5947CA3606E4 Q33948926-73BFF395-001E-4DBB-AD27-A52C7BE407CA Q34084021-9FCC826C-431B-4431-B3F2-0B52637C5A14 Q34117589-E6D96596-5057-4512-ADF7-00A9F1340BE0 Q34288710-E2668A30-3F40-4A85-B19B-1BBB97C06306 Q34297943-023BA50B-A9B1-4CAE-953A-9CBA037ED74F Q34419405-F1B747BC-C3AA-47BC-B102-5AF3AB2F550A Q34504860-0FB05B3F-828E-4006-AE96-F5F755485BA8 Q34580355-2FDD3E31-F2F9-4D74-A7E0-D3A9D8FF09E7 Q34602367-98FB2E1C-1C3F-4C4E-87A9-FC4093F03214 Q34919815-B76DEF0D-C125-48D9-8B3F-CDCD0DDD700D Q35017125-5A6CB7A9-0A80-42D0-951B-52BD16A401C4 Q35040853-BED81097-35AF-4AEC-8E71-21CD3319B36A Q35201923-6A7E3EBD-9A1B-4E0F-814B-547BBEDC0AAE Q35287890-BA3CD9FA-EEB3-40A2-BE4D-96B5EBA01717 Q35395970-6310108D-A0AB-4EA3-8CAB-9CFBAEC2AEF8 Q35552376-877D3CE4-35C6-4203-81F1-57DE062133C0 Q35578544-E5E4F0D3-B71B-423A-B257-CA3B043214A6 Q35591083-3AC8D777-CC10-4786-B1AD-95EFC26632E1

P2860

Targeting the EGFR signaling pathway in cancer therapy.

http://www.wikidata.org/entity/Q34246558

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Targeting the EGFR signaling pathway in cancer therapy.

@ast

Targeting the EGFR signaling pathway in cancer therapy.

@en

Targeting the EGFR signaling pathway in cancer therapy.

@nl

type

label

Targeting the EGFR signaling pathway in cancer therapy.

@ast

Targeting the EGFR signaling pathway in cancer therapy.

@en

Targeting the EGFR signaling pathway in cancer therapy.

@nl

prefLabel

Targeting the EGFR signaling pathway in cancer therapy.

@ast

Targeting the EGFR signaling pathway in cancer therapy.

@en

Targeting the EGFR signaling pathway in cancer therapy.

@nl

P1433

Q34246558-C178EB71-EBE4-4182-9DA3-D2C25F8EF361

P1476

Q34246558-477DD773-A4AE-468D-BDDB-0B7678623307

P2093

Q34246558-9B632319-BABB-4DB4-BD89-EF6068F2599E

Q34246558-B0F88010-C4A4-4294-92B7-33E62DD9DD2C

Q34246558-F6A999F1-0B10-4E72-B33A-98B4D0E100AB

P2860

Q34246558-02C74D02-B146-43B1-A49B-CC7DB3078471

Q34246558-050CB20E-08A5-414B-98E8-CF27697A90AE

Q34246558-09F42E5F-DA03-419B-A7A0-5FFEFA875D0B

Q34246558-0A8EC5A2-536E-41E4-BF85-B2E019D6D3A1

Q34246558-0AD4B59A-3DEA-4E47-B89D-0D6494F690F4

Q34246558-0AE28E32-AA01-495E-B214-7E58DC08E448

Q34246558-0BB5B510-2470-407D-B42E-05A15176327E

Q34246558-0CF0410B-621C-467E-9A75-BA1E92AA6C57

Q34246558-0EE6107D-BF6D-4993-8CB2-5F7319F0ADFB

Q34246558-132FAC93-8328-4D32-9062-A9B92215810A

P304

Q34246558-C7DFB712-06CC-4FBA-8B19-263DE56B5010

P31

Q34246558-CF97E340-81A0-4204-8975-562C410FD8D0

P356

Q34246558-8CE1AE18-E4C7-4276-9E4E-4A8A97E52FD5

P407

Q34246558-A10F1F07-E60D-428B-9759-EFFB2D2A54DF

P433

Q34246558-F4148D1C-703D-44D7-AEDA-5BD6166F3D0A

P478

Q34246558-07EAB841-5DCC-4978-88B8-4BA9764E0BA3

P50

Q34246558-5BE938B2-A91B-4B57-99B4-F947389AD3D7

Q34246558-910B7170-0199-4352-997C-0BC398F802FD

Q34246558-AC52C659-448D-42ED-AD97-BED19DE2DB65

P577

Q34246558-5311C5CB-7C2D-45E9-8B0B-698C391983F4

P5875

Q34246558-7E8A1320-830F-4270-BFCC-E1896AFB6093

P698

Q34246558-DD4234F1-53A5-49D2-88A0-A847BB434D11

P932

Q34246558-A782E8FA-C913-458E-B055-27BBE2C89098

P356

14728222.2011.648617

P1433

Expert Opinion on Therapeutic Targets

P1476

Targeting the EGFR signaling pathway in cancer therapy.

@en

P2093

Dhanya Haridas

http://www.w3.org/2001/XMLSchema#string

Maneesh Jain

http://www.w3.org/2001/XMLSchema#string

Surinder K Batra

http://www.w3.org/2001/XMLSchema#string

P2860

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface

The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.

MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Structure of the extracellular region of HER3 reveals an interdomain tether

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

P304

15-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.2011.648617

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Apar Kishor Ganti

Moorthy Palanimuthu Ponnusamy

Parthasarathy Seshacharyulu

P577

2012-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221742319

http://www.w3.org/2001/XMLSchema#string

P698

22239438

http://www.w3.org/2001/XMLSchema#string

P932

3291787

http://www.w3.org/2001/XMLSchema#string